DIGOXIN - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for digoxin and what is the scope of freedom to operate?
Digoxin
is the generic ingredient in five branded drugs marketed by Glaxosmithkline Llc, Amici, Hikma, Vistapharm Llc, Abraxis Pharm, Hospira, Sandoz, Wyeth Ayerst, Covis, Aurobindo Pharma Ltd, Hikma Intl Pharms, Impax Labs, Novitium Pharma, Rising, Stevens J, Sun Pharm Inds Inc, and Concordia, and is included in twenty NDAs. Additional information is available in the individual branded drug profile pages.There are ten drug master file entries for digoxin. Thirty suppliers are listed for this compound.
Summary for DIGOXIN
| US Patents: | 0 |
| Tradenames: | 5 |
| Applicants: | 17 |
| NDAs: | 20 |
| Drug Master File Entries: | 10 |
| Finished Product Suppliers / Packagers: | 30 |
| Raw Ingredient (Bulk) Api Vendors: | 87 |
| Clinical Trials: | 233 |
| Patent Applications: | 6,794 |
| Drug Prices: | Drug price trends for DIGOXIN |
| Drug Sales Revenues: | Drug sales revenues for DIGOXIN |
| What excipients (inactive ingredients) are in DIGOXIN? | DIGOXIN excipients list |
| DailyMed Link: | DIGOXIN at DailyMed |
Recent Clinical Trials for DIGOXIN
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| State University of New York - Downstate Medical Center | Phase 1/Phase 2 |
| Jacobio Pharmaceuticals Co., Ltd. | Phase 1 |
| Loxo Oncology, Inc. | Phase 1 |
Pharmacology for DIGOXIN
| Drug Class | Cardiac Glycoside |
Medical Subject Heading (MeSH) Categories for DIGOXIN
Anatomical Therapeutic Chemical (ATC) Classes for DIGOXIN
US Patents and Regulatory Information for DIGOXIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Concordia | LANOXIN | digoxin | TABLET;ORAL | 020405-001 | Sep 30, 1997 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Wyeth Ayerst | DIGOXIN | digoxin | INJECTABLE;INJECTION | 084386-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Impax Labs | DIGOXIN | digoxin | TABLET;ORAL | 078556-002 | Jul 20, 2009 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Sandoz | DIGOXIN | digoxin | INJECTABLE;INJECTION | 040481-001 | Aug 21, 2003 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Covis | LANOXIN | digoxin | INJECTABLE;INJECTION | 009330-002 | Approved Prior to Jan 1, 1982 | AP | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Covis | LANOXIN PEDIATRIC | digoxin | INJECTABLE;INJECTION | 009330-004 | Approved Prior to Jan 1, 1982 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for DIGOXIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Glaxosmithkline Llc | LANOXICAPS | digoxin | CAPSULE;ORAL | 018118-002 | Jul 26, 1982 | ⤷ Sign Up | ⤷ Sign Up |
| Glaxosmithkline Llc | LANOXICAPS | digoxin | CAPSULE;ORAL | 018118-001 | Jul 26, 1982 | ⤷ Sign Up | ⤷ Sign Up |
| Glaxosmithkline Llc | LANOXICAPS | digoxin | CAPSULE;ORAL | 018118-004 | Sep 24, 1984 | ⤷ Sign Up | ⤷ Sign Up |
| Glaxosmithkline Llc | LANOXICAPS | digoxin | CAPSULE;ORAL | 018118-003 | Jul 26, 1982 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
